Australie - anglais - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - rosuvastatin calcium -

États-Unis - anglais - NLM (National Library of Medicine)

a-s medication solutions - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 10 mg - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca’s crestor (rosuvastatin calcium) tablets. however, due to astrazeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin calcium tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin calcium tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin calcium tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin calcium tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin calcium tablets are contraindicated in the following conditions: rosuvastatin calcium tab

États-Unis - anglais - NLM (National Library of Medicine)

remedyrepack inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - rosuvastatin 20 mg - pediatric use information for patients 7 to 17 years of age is approved for astrazeneca's crestor (rosuvastatin calcium) tablets. however, due to astrazeneca's marketing exclusivity rights, this drug product is not labeled with that pediatric information. rosuvastatin tablets are indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. rosuvastatin tablets are indicated as an adjunct to diet for the treatment of adult patients with primary dysbetalipoproteinemia (type iii hyperlipoproteinemia). rosuvastatin tablets are indicated as adjunctive therapy to other lipid-lowering treatments (e.g., ldl apheresis) or alone if such treatments are unavailable to reduce ldl-c, total-c, and apob in adult patients with homozygous familial hypercholesterolemia. rosuvastatin tablets have not been studied in fredrickson type i and v dyslipidemias. rosuvastatin tablets are contraindicated in the following conditions: • patients with a known hypersensitivity to any c

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - rosuvastatin calcium -